Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Weighted Average) (2016 - 2025)

Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $133.4 million for Q1 2025.

  • For Q1 2025, Shares Outstanding (Weighted Average) rose 15.66% year-over-year to $133.4 million; the TTM value through Mar 2025 reached $133.4 million, up 15.66%, while the annual FY2024 figure was $119.8 million, 12.21% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $133.4 million in Q1 2025 per ARWR's latest filing, up from $124.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $133.4 million in Q1 2025 to a low of $103.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $110.4 million, with a median of $106.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 1.15% in 2023, then rose 16.23% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $104.5 million in 2021, then grew by 1.44% to $106.0 million in 2022, then increased by 1.3% to $107.4 million in 2023, then rose by 16.23% to $124.8 million in 2024, then increased by 6.82% to $133.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Shares Outstanding (Weighted Average) are $133.4 million (Q1 2025), $124.8 million (Q4 2024), and $119.8 million (Q3 2024).